Albacker, Lee A.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,641

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 242

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 194

Invariant natural killer T cells recognize a fungal glycosphingolipid that can induce airway hyperreactivity

Albacker, L. A., Chaudhary, V., Chang, Y.-J., Kim, H. Y., Chuang, Y.-T., Pichavant, M., DeKruyff, R. H., Savage, P. B., & Umetsu, D. T. (2013) · Nature Medicine

Asthma and respiratory diseasesIL-33, ST2, and ILC Pathways

Cited by 140

Predicting EGFR mutational status from pathology images using a real-world dataset

Pao, J. J., Biggs, M., Duncan, D., Lin, D. I., Davis, R., Huang, R. S. P., Ferguson, D., Janovitz, T., Hiemenz, M. C., Eddy, N. R., et al. (2023) · Scientific Reports

AI in cancer detectionRadiomics and Machine Learning in Medical Imaging

Cited by 40